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Abstract 
The present work evaluates the effect of fumonisin B1 (FB1) on the fatty acid profile of the 
lipid classes of renal and hepatic tissues of piglets. The experiment was conducted at the 
University of Kaposvàr (Hungary) dividing the pigs into two groups: the group treated with 
20 mg of FB1/kg of feed and the control group. The duration of the trial was 10 days, followed 
by the killing of the animals. The analysis of the data showed that there were no significant 
differences between the groups in terms of production parameters and organs weight (liver, 
kidneys and lungs). The fatty acid profile proportion of kidney and liver was slightly 
compromised, suggesting a disturbance of lipid metabolism linked to the inhibition of the 
enzyme ceramide synthase. In the study, a slight change in the composition of membrane 
phospholipids was noted, probably linked to the lipid peroxidation action induced by 
treatment with fumonisins. Although pigs are one of the species most susceptible to 
fumonisins, this experiment has shown that exposure to fumonisins B1 for a short period does 
not induce healthy and biochemical changes. 
  
Riassunto 
Il presente lavoro valuta l’effetto della fumonisina B1 (FB1) sul profilo degli acidi grassi delle 
classi lipidiche dei tessuti renali ed epatici di suinetti. L’esperimento è stato condotto presso 
l’Università di Kaposvàr (Ungheria) suddividendo i suini in due gruppi: gruppo trattato con 
20 mg di FB1 per kg di mangime e gruppo di controllo. La prova è durata 10 giorni seguita 
dall’uccisione dei soggetti. Dall’analisi dei dati è emerso che non ci sono state differenze 
significative tra i gruppi sia per quanto riguarda i parametri produttivi che per quanto riguarda 
il peso degli organi (fegato, reni e polmoni). Le proporzioni del profilo degli acidi grassi di 
reni e fegato è stato lievemente compromesso, suggerendo un disturbo del metabolismo 
lipidico legato all’inibizione dell’enzima ceramide sintasi. Nello studio è stato notato un 
leggero cambiamento nella composizione dei fosfolipidi di membrana, legato probabilmente 
all’ azione di perossidazione lipidica indotta dal trattamento con fumonisine. Sebbene i suini 
siano una delle specie maggiormente sensibili alle fumonisine, questo esperimento ha 
evidenziato che l’esposizione a fumonisine B1 per un breve periodo di tempo, non induce 
cambiamenti a livello biochimico e dello stato di salute.  
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1. Introduction 
1.1 General description of mycotoxins  
Mycotoxins are secondary toxic metabolites produced in nature by moulds growing on plants, 
which have adverse effects on humans, animals and crops that results in diseases and 
economical losses. Mycotoxins are termed as secondary metabolites since they have no 
biochemical significance in fungal growth and development. Not all moulds are toxigenic and 
not all secondary metabolites from moulds are toxic but one toxigenic mould can produce one 
or more of these toxic secondary metabolites (Hussein and Brasel, 2001). Unfortunately, in 
some genera there are species, for example Fusarium verticillioides, in which the 100% of 
the strains are mycotoxins producer under certain environmental conditions (Causin, 2009). 
Nowadays more than 400 mycotoxins are known (Zain, 2011). Mycotoxins are hard to 
classify because of their diverse chemical structures, biosynthetic origin, biological effects 
and their production (Bennett and Klich, 2003). Usually the classification is according to the 
training of the people doing the categorizing. Therefore, under a clinical point of view, 
mycotoxins are classified in relation to the affected organs: hepatotoxins, nephrotoxins, 
neurotoxins, immunotoxins, etc. Cells biologist used to group them in teratogens, mutagens, 
carcinogens and allergens. Even if no one of these is completely satisfactory, mycologist 
classified mycotoxins by the fungi that produce them. For example Aspergillus toxins, 
Penicillium toxins or Fusarium toxins (Bennett and Klich, 2003). Most of the studied 
mycotoxins belong to three genera of fungi: Aspergillus, Penicillium and Fusarium. 
The most recent important epidemic was in 1960 when in England near London, there was an 
unusual veterinary crisis in which approximately 100,000 young turkeys died. It was 
discovered that this turkeys “X” disease was linked to a groundnut meal contaminated with 
alfatoxins, a secondary metabolite of Aspergillus flavus (Bennet and Klich, 2003). Since that 
moment, there was an increasing interest to investigate mycotoxicological effect both in vivo 
and in vitro. 
The major toxigenic species of fungi and their mycotoxins are presented in the following 
table. (Table 1) 
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Table 1: Moulds and mycotoxins of worldwide importance (FAO 2001) 
Mould species Mycotoxins produced 
Aspergillus parasiticus Alfatoxins B1,B2,G1,G2 
Aspergillus flavus Alfatoxins B1,B2 
Aspergillus ochraceus  Ochratoxin A  
Fusarium sporotrichioides T-2 toxin 
Fusarium graminearum Deoxynivalenol 
Zearalenone 
Fusarium verticillioides Fumonisin B1 
Penicillium verrucosum Ochratoxin A 
 
Is well known that exposure to mycotoxins (by ingestion, inhalation or skin contact) can 
develop acute and toxic effects both in humans and in animals depending on the type of 
mycotoxins, level of exposure, the species, and the susceptibility of an animal within a species 
(Zain, 2011; Loi et al., 2017; Hussein and Brasel, 2001; Udomkun et al., 2017; EFSA, 2014; 
Fao/Iaea, 2001; WHO and FAO, 2012; Gowda et al., 2017; Pleadin, 2015; Zaki et al., 2012; 
CAST, 2003). Another main aspect to take in account is the interaction between mycotoxins 
named multi-toxic effect. Usually, feed is contaminated with multiple mycotoxins. For 
example, aflatoxin and fumonisin B1 commonly occur together in the same grain. In 1993 the 
World Health Organization and the International Agency for Research on Cancer (WHO-
IARC, 1993a,b) classified alfatoxins as carcinogenic to humans (Group 1), ochratoxins and 
fumonisins were classified as possible carcinogens for humans (Group 2B) while 
trichothecenes and zearalalenone were classified as not carcinogenic for humans (Group 3). 
Since these toxic compounds are transferred to animas with plants, and to humans with animal 
products, they could infect all the food chain. To protect the European consumers the 
European Food Safety Authority (EFSA) suggested to the European Commission, not only 
set the maximum level of mycotoxins in food and feed to guarantee humans and animals 
healthiness (Commission Regulation, 2006; European Parliament 2002/32/EC). They also 
gave a regulation about the sampling methods for the official control of the mycotoxins level 
(Commission Regulation 401/2006). However, the safety limits recommended are very 
different and depend on the country regulation and even species.  
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Focusing on the principal types of mycotoxins, alfatoxin B1 is the most potent natural 
carcinogenic known (Squire, 2017). Alfatoxins are produced by different species of the 
genera Aspergillus. In farm animals, AFB1 can cause liver dysfunction, reduction in egg and 
milk production and a long-term exposure, can result in an embryo toxicity; AFB1 has also 
been shown to exert an immunosuppressive activity. The Aspergillus formation and the 
presence of AFB1 in maize are favoured by hot and dry season and storage. Indeed in Croatia 
in 2013, an extremely warm year, 38.1% of maize samples were contaminated by AFB1 and 
the 28.8% of the samples contained this toxin in levels higher than the maximum permitted 
level (Pleadin, 2015). Another important group of mycotoxins are the ochratoxins. In this 
group, ochratoxin A is the major metabolite of toxicological significance and is a frequent 
natural contaminant of many foodstuff like cereals, beans, fruits, fish, eggs and milk (Pleadin, 
2015).  
Fumonisins are a group of cancer-promoting metabolites, produced by Fusarium spp., which 
are associated with several mycotoxicoses. In animals fumonisins damage the liver and 
kidneys, decrease weight gain and increase mortality rates (Akande, 2006). Fumonisin B1 is 
identified as the most toxic metabolite, and the most sensitive species are pigs (pulmonary 
edema) and horses (equine leukoencephalomalacia) (Efsa, 2014).  As Fusarium is among the 
most prevalent fungi on maize, it was noted that consumption of maize contaminated with 
fumonisins is associated with elevated occurrence frequency of human oesophageal cancer 
incidence in various parts of Africa, China and Iran but especially in South Africa (Zain, 
2011).  
One more kind of mycotoxins produced by Fusarium spp. are trichothecenes. The toxic 
actions generated by this class are necrosis of the oral mucosa and skin in contact with the 
toxin, acute effect on the digestive tract and decrease immune function (Schwarzer, 2009). 
There are two types of trichothecenes: type A included T-2 toxin (T-2), HT-2 toxin (HT-2) 
and diacetoxiyscirpenol (DAS); type B is represented by fusarenone-X (FUX), 
deoxynivalenol (DON) and nivalenol (NIV). Type B have a relatively low toxicity compared 
to type A trichothecenes, but this varies with species and cell types (Loi et al., 2017).   
An additional mycotoxin produced by Fusarium moulds is zearalenone. This mycotoxin is 
known for its ability to inhibit the binding estrogenic hormones, resulting in fertility problems 
5 
 
in both humans and animals (Udomkun et al., 2017; Zain, 2011). Generally, ruminants are 
more resistant to mycotoxins due to the rumen microbial population. As Kiessling et al. (1984) 
describe, the rumen flora is able to convert some mycotoxins to less toxic metabolic 
compounds or even inactivate them at common exposure levels by bio-hydrogenation or 
deamination.  
All mycotoxins are low-molecular-weight natural products. These compounds are produced 
in cereal grains during and after harvest (field and storage types) in various conditions and 
they can contaminate a wide range of commodities both pre and post harvesting. The 
production of mycotoxins in food and feed supply chain is a result of a multi factors 
combination like storage, environmental and ecological conditions. For example during the 
production phase in the field, temperature, water activity and insect infestation are favourable 
factors for fungal growth and proliferation. In the post-harvest scenario, handling and 
transportation systems are very important factors to keep the mycotoxins development under 
control (Paterson et al., 2010). 
 It is calculated that approximately 25% of the world’s agricultural commodities are 
contaminated with mycotoxins (Quiroga et al., 2009). The cost produced by mycotoxins’ 
commodities contaminations account for billion dollars every year (Wu, 2007). In CAST 
(2003) is reported that in the United States the mean economic annual cost of crop losses from 
alfatoxins, fumonisins and deoxynivalenol is 932million dollars. Even if is difficult to 
quantify the economic impact caused by mycotoxins, it is possible to summarize it in two 
categories. Direct losses, which are related to lowered crop yield, reduction of animal 
performance and the cost associated with the animal diseases; and indirect losses, which 
concern increased use of fungicide, reduction in the value of the commodities, veterinary-care 
cost, investments in strategies to reduce the problem (Loi et al., 2017). 
As we can see from the BIOMIN mycotoxin survey (Figure 1), the contamination is spread 
all over the world.  
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In this survey 16.511 samples were analysed from January to December 2016 providing an 
overview on the incidence of the principal types of mycotoxins contained in the primary 
components used for feed as corn, wheat, barley, rice, soybean meal, corn gluten meal, dried 
distillers grains and silage (BIOMIN survey, 2016). The samples were derived from 81 
different countries in the world and 63.000 analyses were performed. The assessment revealed 
an average of 28 mycotoxins and metabolites per sample and 9 out of 10 samples were 
contaminated with Fusarium toxins, Aspergillus toxins or both. Another interesting data is 
that the 94% of the samples contained 10 or more mycotoxins or metabolites. The survey 
divides the world in sub-regions and gives the opportunity to concentrate the attention on 
South Europe, Central Europe and North Europe. As shown in table 2 in the Southern Europe 
the total risk is 61% with a noticeable predominant of fumonisins (74%) followed by 
deoxinivalenol (46%). 
Figure 1: Global map of mycotoxin occurrence and risk in different regions between July            
and December 2016 (BIOMIN mycotoxin survey 2016) 
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Table 2: Regional overview (BIOMIN mycotoxin survey 2016) 
Southern Europe Total 
Risk 61% 
Central Europe Total 
risk 60% 
Northern Europe Total 
Risk 67% 
 Alfa 38% Alfa 10% Alfa 1% 
ZEN 35% ZEN 51% ZEN 46% 
DON 46% DON 73% DON 77% 
T2 7% T2 21% T2 18% 
FUM 74% FUM 50% FUM 12% 
OTA 26% OTA 12% OTA 13% 
 
Nevertheless, it is impossible to completely avoid the production of mycotoxins, but the 
contamination could be mitigated through strategic interventions. The “Codex Alimentarius” 
(WHO and FAO, 2012) contains general principles for the reduction of various kinds of 
mycotoxins in cereals, taking into account the different climate, crops and agricultural 
systems of each country. The recommendations are divided in Good Agricultural Practices 
(GAP’s) like harvesting in the right time, crop rotation, avoid overcrowding; and Good 
Manufacturing Practices (GMP’s) like drying to a safe moisture level, cleaning of the 
containers, measuring the temperature. Other studies show how to remove or inactivate 
mycotoxins using different chemicals like propionic acid, ammonia, copper sulfate, benzoic 
acid, urea, citric acid, and others. However, these ones are unpractical on food because of 
their potential toxic activity, poor efficacy, high costs and negative effects on the quality 
(Gowda et al., 2017; Loi et al., 2017). It is demonstrated that mechanical heat treatment, 
irradiation and use of adsorbents are able to remove contaminated fractions of food and feed. 
However, this approach can have some possible negative disadvantages as binding essential 
nutrients like minerals and vitamins and thus reducing their availability (Yadav, 2017; Loi et 
al., 2017). There are also biological methods, like degradation of mycotoxins into non-toxic 
metabolites by using fungi, bacteria or enzymes. During the biotransformation, these living 
microorganisms are able to metabolize, destroy or deactivate toxins resulting in less 
dangerous compounds. In any case, if the mycotoxins’ contamination level is very high, the 
microorganisms can be altered or inhibited. This means that the time to rise a satisfactory 
decontamination level becomes longer (Loi et al., 2017).  
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1.2 Fusarium spp. 
Fusarium spp. is a huge genus manifested worldwide. The widespread diffusion of Fusarium 
spp. is due to the ability of these fungi to grow on different kinds of substrates for example 
on soil, subterranean and areal plant parts, plant debris, and other organic substrates (Nelson 
et al., 1994). Living on dead or decaying organic matter, the major part of Fusarium spp. are 
called “saprophytes”. Even if not all the Fusarium species are able to synthesise dangerous 
molecules, most of them are able to produce a large variety of mycotoxins with various action 
pathways. Secondary fungi metabolites adversely affect plants, animals and humans, causing 
toxic effects. This genus is well know as a plant pathogen that can cause rots, wilts and other 
diseases. Fusarium species infect and produce mycotoxins in wheat, corn, rice, barley, oats 
and other cereals and forages that are a consistent or predominant part in humans and animals 
diets. For example in most regions of the world, Fusarium graminearum is the major causal 
agent of head blight (or scab) in wheat and red ear rot of corn (CAST, 2003). Thus, the 
presence of this genus in the fields and harvest, results in an economical and sanitary 
consequences. Most of the contamination starts in the field due to an infection. During the 
storage, in order to minimize the spread of the mycotoxins, the most important factor is the 
control of moisture level and temperature.   
There are many species, and population within species, that make Fusarium very difficult to 
classify. The variations can be morphological, cultural and physiological, that may explain 
the ability of Fusarium to be ubiquitous. It is also noted that Fusarium spp. require lower 
temperatures and higher humidity for growth and production of mycotoxins than the genus 
Aspergillus. However, Fusarium spp. is also common in tropical regions and is found in the 
desert, alpine and artic areas where severe climatic conditions prevail (Nelson et al., 1994).  
The optimal temperature conditions to develop and produce fumonisins are widely different, 
according to the considered fungal strain. Under laboratory conditions, Fusarium 
verticillioides strain MRC 826 (the strain of F. verticillioides used in all experiments, 
originally isolated from corn in Transkei, Southern Africa 1975) grows rapidly on potato 
dextrose agar at 25°C in aerobic condition. It spreads in woolly or cottony colonies, as a 
typical filamentous fungus. In field, its development is favourite by a temperature between 
22.5 °C and 27.5 °C but in some cases, it can rise up to 30°C, according to the origin area. 
For example, Fusarium verticillioides coming from a temperate zone has an optimum 
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temperature at 30°C. This fungus has a water activity (aw) 0.98, proving that it requires a high 
quantity of water. In the cornfields, the infection can start in three ways: infect seeds as a 
spore, only apparently heathy, and ready to activate when the environmental conditions are 
suitable; through inoculated fungi in the soil; because of insects attacks that can damaged the 
plants or the seeds, facilitating the infestation. If the spreading occurs, the harvest must be 
destroyed or mixed with uncontaminated crop to reach an acceptable level for human or 
animal consumption.  
It is impossible to completely eliminate the contamination caused by mycotoxins on the 
commodities. However is possible to prevent and reduce the occurrence of the Fusarium 
species through the adoption of good agricultural practices. These principles are illustrated in 
the Commission Recommendation 2006/583/EC “on the prevention and the reduction of 
Fusarium toxins in cereal and cereals product” (Commission Recommendation 2006/576/EC, 
2006) and in  the “Codex Alimentarius”(WHO and FAO, 2012). As mentioned above the 
fundamentals cited in these documents are generals and have to be applied in relation to the 
local situations (crops, climate and agronomic practices). The most important factors to take 
in account are: crop rotation, choice of variety/hybrid, crop planning, soil and crop 
management, harvesting, drying, storage, transport from storage. It is clear that the application 
of the good practices is not enough to contrast the development and the spread of the Fusarium 
spp. and other treatments are necessary. Physical, biological and chemical treatments can be 
used but with a variable degrees of success (Sweeney and Dobson, 1998). All of these 
procedures should inactivate, destroy or remove the mycotoxin; the process must not cause 
the release of toxic substances, metabolites or by-products in the food or feed; retain nutrient 
value and feed acceptability of the product or commodity; there must not be alterations of the 
product’s technological properties (CAST, 2003). 
To detect the presence of mycotoxins, testing of the commodities is required. This procedure 
starts with correct sampling. The samples must be representative of the entire lot, taking an 
adequate size sample. The next steps are sample preparation, extraction of the toxin into an 
extraction solvent and analysis. There are different methods of analysis such as 
chromatographic methods i.e.: thin layer chromatography (TLC), high-performance liquid 
chromatography (HPLC) and gas chromatography (GC); fluorescence procedure or immune 
enzyme test like enzyme-linked immunosorbent assay (ELISA). The decision between these 
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methods is based on three criteria: speed of analysis perform, technical skill level required to 
perform the test and if the assay afford a qualitative or quantitative result (CAST, 2003).  
The main mycotoxins classes produced by Fusarium are: trichothecenes, zearalalenone and 
fumonisins (Placinta et al., 1999). In a survey of Griessler et al. (2010), over a 4.5 years period 
the incidence of mycotoxins was assessed in feed materials and compound feed in five 
Southern European countries including Spain, Greece, Portugal, Cyprus and Italy. The 
collected samples were analysed with two different methods (HPLC and ELISA) for the most 
relevant mycotoxins as alfatoxins, zearalenone (ZEA), trichothecenes A and B, fumonisins 
and ochratoxin A. It was discovered that the Fusarium mycotoxins were the major 
contaminants. In Italy, 72% of the samples were positive for the trichothecenes type B, 73% 
for the fumonisins and 35% for zearalenone. It was observed a high average fumonisins 
contamination on maize (especially in the north of Italy) compared to the other regions 
surveyed.  
1.2.1 Trichothecenes 
Trichithecenes is a group of mycotoxins produced by different types of Fusarium species. 
Although it is known that other genera of fungi are able to produce trichothecenes (Bhat et 
al., 2010; Sweeney and Dobson, 1998), the most important are F. equiseti, F.graminearum, 
F. verticillioides and F. sporotrichioides (Sweeney and Dobson, 1998). This large family was 
named after the compound trichothecin, which was one of the fist members identified. All the 
trichothecenes contained a sesquiterpe rings characterized by a 12,13-epoxy-tichothec-9-ene 
nucleus. The toxicity of this group is given by the 12,13-epoxide ring. Based on the position 
of their functional group, trichothecenes are classified into four groups: A, B, C and D. The 
most common are: type A that includes T-2 toxin (T-2), HT-2 toxin (HT-2) and 
diacetoxiyscirpenol (DAS); and type B represented by fusarenone-X (FUX), deoxynivalenol 
(DON) and nivalenol (NIV). Type A trichothecenes are more toxic than type B trichothecenes 
(CAST, 2003; Bhat et al., 2010). Fusarium graminearum produces DON and NIV. It has an 
optimal growth range between 24-26°C and it requires a minimum aw of 0.90. One of the most 
common producer of T-2 toxin, DON and NIV is Fusarium sporotrichioides. It has an 
optimum growth range between 22.5 and 27.5°C and the minimum aw is 0.88 (Sweeney and 
Dobson, 1998; Fao/Iaea, 2001). Trichothecenes are not degradable during food processing, 
they are stable at neutral and acid pH, and thus are not hydrolysed in the stomach after the 
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ingestion (Loi et al., 2017). 
Trichothecenes are strong inhibitors of eukaryotic protein and DNA synthesis and are 
associated with several effects on animal systems such as immunologic effects, hematopoietic 
effects, and nephrotoxicity (CAST, 2003; Zain, 2011). Mycotoxins that belong to the family 
of trichothecenes are amphiphilic (both hydrophilic and lipophilic), with a low-molecular 
weight. This means that they can move through cell membranes passively and be easily 
absorbed by the gastrointestinal tract. Common symptoms are anorexia, weight loss, poor 
feed utilization, vomiting, bloody diarrhea, dermatitis, abortion and death. A general 
overview is given in table 3. 
 
Table 3: Commodities in which mycotoxin contamination has been found and the resulting 
effects on animals and humans (CAST, 2003) 
Mycotoxin 
Commodities 
found 
contaminated 
Effects of mycotoxins 
Affected species 
Pathological 
effects 
Trichothecenes  
(T-2 toxin, DAS, 
NIV, DON, HT-2 
toxin, FUX) 
Corn , wheat, 
commercial 
cattle feed, 
mixed feed 
Swine, cattle, 
chicken, turkey, 
horse, rat, dog, 
mouse, cat, 
human 
Digestive disorder 
(emesis, diarrea, 
refusal to eat) 
Hemorrage 
(stomach, heart, 
intestine, lungs, 
bladder, kidney) 
Edema 
Oral lesions 
Dermatitis 
Blood disorders 
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Among type A, T-2 is the most important. T-2 is a common contaminant of grains both in 
Europe and the United States (CAST, 2003). It is present in wheat, rye, soybeans and maize 
(Kanora and Maes, 2009) and is particularly related with wet harvest (Fao/Iaea, 2001). When 
ingested it is metabolized by the gut microflora of mammals into other metabolites; the first 
metabolite is HT-2 toxin which is absorbed into the blood (Bhat et al., 2010). It is probable 
that T-2 toxin caused the disease called “alimentary toxic aleukia” which affected entire 
villages in Siberia after the Second World War. Symptoms are vomiting, fever, acute 
inflammation of the alimentary tract and blood anomalies. T-2 is the most toxic compound 
that causes dermal toxicity. It was demonstrated that after 24 h from the application it causes 
an edema. In guinea pigs, T-2 toxin caused erythema on the shaved backs at dose of 5ng 
(CAST, 2003). In poultry, T-2 is associated with mouth and intestinal lesions, decrease of 
feed consumption, weight loss and decrease of eggs production (Zaki et al., 2012). T-2 is the 
most harmful Trichothecene on the reproductive system of pigs. In one study, a low 
concentration of this toxin in the feed (1-2 mg/kg) of pregnant sows during the last third of 
gestation was sufficient to induce an inhibitory effect on the ovaries, histological degeneration 
and atrophy.  
DON is a notable contaminant of corn, barley and wheat (CAST, 2003). Vomitoxin, the other 
name of DON due its emetic effect, is highly stable and can survive at various food-processing 
methods as milling and powdering (Bhat et al., 2010). In animals it causes neurotoxic effect 
demonstrated by vomit at high doses (20 mg DON/kg feed) and feed refusal at low doses (12 
mg DON/kg feed), resulting in a loss of productivity and immunosuppression (CAST, 2003; 
Bennett and Klich, 2003; Pierron et al., 2016). Concerning farm animals, monogastrics are 
more sensitive to DON especially swine, followed by poultry and ruminants. Indeed in the 
(Commission Recommendation 2006/576/EC, 2006) concerning the presence of some 
mycotoxins in products intended for animal feeding, the amount of DON in complementary 
and complete feeding stuffs for pigs is 0.9 ppm instead of 5 ppm. In a meta-analysis (Andretta 
et al., 2012) it is reported that DON reduced feed intake and weight gain by the 26% in pigs.   
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1.2.2 Zearalenone 
Zearalenone is a mycotoxin produced primarily from Fusarium graminearum, which is 
naturally present in high-moisture corn. High humidity and low temperatures promote the 
mycotoxin biosynthesis on food and feed stuffs. Zearalenone is a common contaminant of 
corn, wheat, barley and grain sorghum (CAST, 2003). Zearalenone is difficult to be 
eliminated or decomposed during food and feed processing because it is heat-stable (Zaki et 
al., 2012). Usually it is present with others mycotoxins such as trichothecenes and in particular 
DON. The most notable effect of this mycotoxin on animal is on the reproductive system, but 
it also can cause teratogenic effects (CAST, 2003). When zearalenone is ingested, it is 
absorbed in a very high ratio (in pig 80-85% was estimated (Zinedine et al., 2007)). It is 
processed in the liver where is hydroxylated and results in two different metabolites: α-
zearalenol and β-zearalenol. Zaralenol, the reduced form of zearalenone, increase estrogenic 
activity and was used as an anabolic agent for both sheep and cattle. In 1989 it was banned 
from the European Union, but is still used in other parts of the world (Bennett and Klich, 
2003). Zearalenone and its metabolites induce reproductive disorders, mimicking the effect 
of estrogens due to the structural similarity with that molecule. Low dose of ZEN results in  
feminization while at high concertation ZEA interferes with ovulation, conception, 
implantation and foetal development (CAST, 2003). In pregnant animals, it is associated with 
embryonic death and abortion. Swine are particularly sensitive to ZEA, showing a 
physiological response when the level of this mycotoxin exceeds about 1 mg/kg of feed 
(CAST, 2003). Symptoms of hyperestrogenism caused by ZEA are swelling of the vulva, and 
enlargement of the mammary glands, especially in prepubescent gilts. In young male pigs, 
zearalenone induces feminization by causing testicular atrophy, swelling of the prepuce and 
mammary glands enlargement. Young piglets can be affected through sows’ milk, provoking 
estrogenism. Other effects induced by ZEA are anestrous, nymphomania and pseudo-
pregnancy. In dairy animals zearalenone promotes reduced feed intake, decreased milk 
production, vaginitis, increase of vaginal secretion, low reproductive performance and 
mammary glands enlargements (Zinedine et al., 2007). In the (Commission Recommendation 
2006/576/EC, 2006) the maximum level  permitted in feed materials is 2 ppm (exception for 
the maize by-product 3 ppm) but the quantity in complete and complementary feedstuffs for 
the most sensitive animals is low. For example in piglets and gilts, the level of ZEA is 0.1 
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ppm; sows and fattening pigs have the limit at 0.25 ppm, and in feed for calves, dairy cattle, 
sheep and goats the limit is 0.5 ppm. A general overview is given in table 4. 
 
Table 4: Commodities in which mycotoxins contamination have been found and the resulting 
effects on animals and humans (CAST, 2003) 
 
 
 
 
 
 
 
Mycotoxin 
Commodities 
found 
contaminated 
Effects of mycotoxins 
Affected species 
Pathological 
effects 
Zearalenone Corn , moldy 
hay, pelleted 
commercial feed 
Swine, dairy 
cattle, chicken, 
turkey, lamb, rat, 
mouse, guinea 
pig 
Estrogenic effects 
(edema of vulva, 
prolapse of 
vagina, 
enlargement of 
uterus) 
Atrophy of 
testicles 
Atrophy of 
ovaries, 
enlargement of 
mammary gland 
Abortion 
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1.3 Fumonisins 
The most important mycotoxins relatively to this study are fumonisins. It is proved that 
fumonisin mycotoxins are responsible for the major toxicological and carcinogenic effects 
caused by corn cultures in experimental animals.   
1.3.1 Isolation, Identification and Structure 
Fumonisins are produced by fifteen Fusarium species but the most important producers are 
F. verticillioides and F. proliferatum because of their worldwide distribution, particularly on 
maize. In order to detect cancer-promoting compounds, Gelderblom et al. (1988) firstly 
isolated and purified fumonisin mycotoxins from culture material of the most studied strain 
of Fusarium moniliforme (formerly= verticillioides) MRC 826. Gelderblom et al. (1988) 
known that the culture material of F. Moniliforme MRC 826 is hepatocarcinogenic in rats and 
cause LEM in horses. They established a bioassay to understand if fractions isolated from 
culture material of each toxic strains were correlated with the cancer-promoting activity by 
incorporating them in the rat feed. Rats were initiated with a diethylnitrosamine (DEN) 
treatment (as a cancer initiator) and the induction of γ-glutamyltranspeptidase positive 
(GGT+) foci (as end point). After four weeks of treatment, rats were killed and their livers 
were subjected to histochemical analyses. Culture material was extracted with ethyl acetate 
and CH3OH-H2O (3:1) by blending and filtering. The extract was evaporated and partitioned 
between CH3OH-H2O (1:3) and CHCl3. The CH3OH-H2O fraction was chromatographed on 
an Amberlite XAD-2 column, and the active part was eluted with CH3OH. This fraction was 
chromatographed on a silica gel column with CHCl3-CH3OH-CH3COOH (6:3:1) and later 
purified on a C18 reverse-phase column. Two compounds were obtained in pure form and 
were chemically characterize by nuclear magnetic resonance and mass spectroscopy: 
fumonisin B1 and fumonisin B2 (Figure 2).  
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Figure 2: Chemical structure of Fumonisin FB1 and FB2 
 
Since than, 28 fumonisins analogs have been characterized. Fumonisins are divided in four 
main groups: A, B, C and P series, which contain two tricarballylic acid moieties. The FB 
analogs are the most abundant naturally occurring fumonisins (Rheeder et al., 2002) and in 
particular FB1 is found at the highest level (from 70% to 80% of the total fumonisins 
produced) (Marasas, 1996).   
1.3.2 Natural occurrence  
The two major fumonisins FB1 and FB2 occur mainly in maize and maize products at a global 
level (Visconti et al., 1995; Sydenham et al., 1990; SCOOP TASK, 2003; Griessler et al., 
2010; Zinedine et al., 2007; Waśkiewicz et al., 2012; Zaki et al., 2012; Shephard et al., 1996). 
The first conclusive report of the natural occurrence of FB1 in corn is the study of Sydenham 
et al. (1990). In this study, they collected home-grown corn from the Transkei area, in 
Southern Africa, in order to analyse the presence of the fumonisin mycotoxins. Using two 
high performance liquid chromatography procedures and a capillary gas chromatographic-
mass spectrometric procedure, they confirmed the presence of fumonisin B1. This evidence 
suggested that humans living in that area may well be exposed to the cancer-promoting 
activity of the fumonisins. 
The occurrence of fumonisins in Europe was assessed many times through different studies. 
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For example Visconti et al. (1995) summarize in their article two consecutive studies ordered 
by The European Commission, Community Bureau of Reference and Measurement and 
Testing Programme in which they wanted to improve the quality of fumonisins analysis at 
European level. In this study they confirmed that the highest production of fumonisins was 
obtained with isolates from maize (1,259 µg FB1/g), followed by isolates from wheat (769 µg 
FB1/g) and barley (320 µg FB1/g). Furthermore, they investigated the natural occurrence of 
FB1 and FB2 in different countries and in different inbred lines of maize, calculating the 
incidence and the levels of fumonisins.  The highest contamination was found in Italy and 
Portugal with 100% of incidence and fumonisins levels up to 2.85 and 4.45 µg/g, respectively. 
However, in countries like Croatia, Poland and Romania very low levels of contamination 
were found. This suggests that the environment of a specific area of cultivation and storage 
conditions plays a role in the formation of fumonisins in maize.  
An interesting data for the Italian population is the high contamination levels found in maize 
flour or polenta. About 85% of the samples collected in Italy, showed fumonisin levels higher 
than 1 mg/kg, the maximum level admitted. This implies that FB1 is stable during most types 
of processing, even if the concentration is reduced during the manufacture of corn-starch by 
wet milling because FB1 is water-soluble. Particular attention should be given to the link 
between the increased consumption of maize based products in the north-east of Italy and the 
increased risk of incidence of human oesophageal cancer.   
Another report was conducted in 2003 (SCOOP TASK, 2003) to provide information on the 
exposure of the population of EU Member States to fumonisins. This report confirmed that 
cereals, in particular corn and wheat, are the major source of intake of FBs.  
In 2016, BIOMIN (2016) conducted their annual survey to monitor the spread of mycotoxins 
in the primary components used for feed in the world. In 2016, fumonisins were the second 
source of contamination in corn in Europe: 67% of samples contaminated with fumonisins 
had an average concentration of 2057 mg/kg. 
1.3.3 NOEL, TDI 
The no-observed-adverse-effect-level (NOAEL) is the level of exposure of an organism that 
has no biologically or statistically significance when compared to its appropriate control 
(www.wikipedia.org). The NOAEL depends on the time of exposure to the mycotoxins, in 
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this case to FB1. Acute toxicity is studied in one dose; subacute toxicity concerns a repeated 
dose (14-28 days); sub-chronic toxicity implies that the administration involves 10-25% of 
the life of the animal while chronic toxicity regard more than 50% of the life of the animal. 
Different studies have been conducted to different animals in order to determine the limit of 
exposure to FB1. Anyhow, cell apoptosis is one of the observation to determine the NOAEL 
in experimental animals. The dose level causing apoptosis is quite different according to the 
duration of exposure, the form of the fumonisins (pure or fungal culture) and the species. For 
example in pigs and horses, some typical effects are porcine pulmonary edema (PPE) and 
equine leukoencephalomalacia (ELEM). The NOAEL for PPE in pigs fed with FB1 is lower 
than 50 mg FB1/kg BW/day. The NOAEL for ELEM in horses fed with FB1 is lower than 0.2 
mg FB1/kg BW/day. Some examples of NOAEL are shown below (Table 5). 
 
Table 5: NOAELs from different studies expressed as mg FB1/kg BW (Scientific Committee 
on Food, 2000) 
Species Duration Target organ NOAEL Reference 
Rat Short-term Liver <0.75 
Gelderblom et 
al, 1994 
Pig Short-term Lung/PPE <4.5 
Motelin et al, 
1994 
Horse Short-term Brain/ELEM 0.2 Ross et al, 1994 
Mouse Sub chronic Liver 1.8 Voss et al, 1995 
Rat Sub chronic Kidney 0.2 Voss et al, 1995 
Rat Chronic Liver 1.25 
Gelderblom et 
al, 1995 
Mouse Chronic Liver 0.6 NTP, 1999 
 
 
The tolerable-daily-intake is an estimate of the amount of a contaminant in food or water that 
can be ingested daily throughout life without causing any appreciable risk to health. In the 
WHO/IARC (2002) they evaluated the risk of human exposure to FB1 and they confirmed the 
previous evaluation, made in 1993, that there is inadequate evidence of carcinogenicity of 
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fumonisins, so FB1 is possibly carcinogenic to humans (Group 2B). However, there is 
sufficient evidence in experimental animals for the carcinogenicity of FB1. The Scientific 
Committee on Food of the European Commission concluded that the TDI for FB1, FB2 and 
FB3, alone or in combination is 2 µg/kg BW per day (SCOOP TASK, 2003; Commission 
Regulation 1881/2006, 2006; http://ec.europa.eu/food/fs/sc/scf/out185_en.pdf).  
Taking into account the maximum tolerable level of mycotoxins ingested by livestock, the 
European commission recommended guidance values. Deoxynivalenol, zearalenone, and 
fumonisins FB1 and FB2 are transferred at an only limited extent from feed into meat, milk 
and eggs and so food from animal origin can contribute only marginally to the total human 
exposure to these toxins (Commission Recommendation 2006/576/EC, 2006). The limit of 
human food contamination is used as a reference also for animal feedstuffs. The maximum 
levels for certain contaminants in foodstuff is regulated by the (Commission Regulation 
1881/2006, 2006). However, the European Commission has set a maximum level of 
contamination in products intended for animal feeding as shown in the following table (Table 
6). 
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Table 6: Guidance Values in products intended for animal feeding (Commission 
Recommendation    2006/576/EC) 
Mycotoxin Products intended for 
animal feed 
Guidance value in 
mg/Kg (ppm) relative 
to a feed stuff with a 
moisture content of 
12% 
Fumonisin B1+ B2 Maize and maize products  60 
Complementary and 
complete feedstuffs for: 
 
 Pig, horse, rabbits and 
pet animals  
5 
 Fish 10 
 Poultry, calves and 
lambs 
20 
 Adult ruminants and 
mink 
50 
 
1.3.4 Mode of action 
In all animal studied, including pigs, fumonisins are rapidly adsorbed but the quantity of FB1 
detected in tissues after oral administration is very low (˂ 4% of the dose). This denotes that 
the accumulation of fumonisins is less than expected based on the relative amounts in the feed 
(WHO and FAO, 2012; Riley and Voss, 2006).  
The toxicity of fumonisins is due to the structural similarity to the cellular sphingolipids, and 
this similarity causes the disruption of lipid metabolism. The disruption of lipid metabolism 
implies alterations of lipid composition of cell membranes, changes in intracellular and 
extracellular concentrations of lipid mediators, alteration in the expression and activity of 
signalling and regulatory pathways that control physiological processes critical for cell 
growth, differentiation and normal cell function (FAO/WHO, 2012). The mode of action of 
fumonisins is firstly explained by the interference with the de novo synthesis of sphingolipids, 
in particular because of the structural similarity with sphingosine (So).  
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Sphingolipids are a class of lipids found in all eukaryotic cells as well as some prokaryotic 
organisms and viruses. Nowadays over 300 sphingolipids have been identified, and the 
common trait is a long chain base backbone (sphingoid base). The most common sphingoid 
base in mammals is sphingosine but other frequently occurring sphingoid bases are 
sphinganine and 4-hydroxysphinganine. The functions of sphingolipids are multiple because 
they are involved in the regulation of cell growth, differentiation, neoplastic transformation, 
participation in cell-cell communication and cell-substratum interactions and interactions 
with cell receptors and signalling system (Wang et al., 1991). The first step of the sphingolipid 
biosynthesis started with the condensation of the amino acid L-serine and a fatty acid as the 
palmitoyl-CoA, covered by the catalysed enzymatic reaction from the enzyme serine-
palmitoyl-transferase. From the reaction a molecule of CO2 and 3-ketosfinganine fatty acid 
are released. In the next step, the 3-ketosfinganine is reduced in D-erythro-sphinganine or 
sphinganine (Sa) by the enzyme 3-ketosfinganine reductase NADPH-dependent. The 
sphinganine undergoes an acylation with a molecule of acyl-CoA, catalysed by sphinganine 
N-acyltransferase, producing dihydroceramide or D-eritro-dihydroceramide. The latter is 
converted to ceramide by dihydroceramide desaturase. Thus, ceramide can be used for the 
biosynthesis of sphingomyelin, glycosphingolipids or phosphorylated sphingolipids such as 
sphingosine 1-phosphate. This reaction takes place in two successive phases. In the first 
phase, the cellular enzyme ceramidase by deacylation of ceramide produces a sphingosine 
molecule (So). In the second phase, the enzyme sphingosine kinase catalyse the 
phosphorylation of the sphingosine giving sphingosine 1-phosphate. The sphingosine 1-
phosphate can be reconverted into sphingosine through sphingosine 1-phosphate phosphatase, 
or can be divided by sphingosine 1-phosphate lyase into ethanolamine 1-phosphate and into 
a C16-acyl-aldehyde fatty acid (Merrill and Sandhoff, 2002).          
As shown in the figure below (Figure 3), fumonisin B1 inhibits a key enzyme in the de novo 
biosynthesis of sphingolipids known as ceramide synthases (sphingoid base N-
acyltransferase) (Enongene et al., 2000; WHO/IARC, 2002). The explanation for why 
fumonisins inhibit the de novo ceramide biosynthesis is because they have a primary amino 
group at the C2 position which bind ceramide synthase and prevent the CoA-dependent 
acylation of sphinganine (Sa) (Voss et al., 2011). Most notably the recent discovered 1-
deoxysphinganine which, like fumonisin, lacks a hydroxyl group on C1 and is found in large 
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quantities in liver of mice fed diets with FB1 (FAO/WHO, 2012).   
 
 
Figure 3: Outline of the de novo sphingolipid biosynthetic pathway and modality of the 
activity of FB1 (Enongene et al., 2000)  
 
The major biochemical and cellular consequences of fuminisin inhibition of ceramide 
synthases are the accumulation of free sphingoid bases and their 1-phosphates in tissues, 
serum and urine. The increase of sphingosine (So), although to a lesser extent than 
sphinganine, is caused by the inhibition of ceramide synthase, which promotes the acylation 
of sphingosine. Another consequence is the depletion or alteration of more complex 
sphingolipids and decreased ceramide and ceramide 1-phosphate biosynthesis (Voss et al., 
2007; Voss et al., 2011; FAO/WHO, 2012; Gelderblom et al., 1997). Free sphingoid bases 
and ceramide can induce cell death, so the inhibition of ceramide synthase can inhibit cell 
death. On the other hand, redirection of sphinganine into sphinganine 1-phosphate is a 
potential survival signal stimulating cell proliferation. For this reason, fumonisins have been 
used to demonstrate the role of sphingosine 1-phosphate, ceramide and more complex 
sphingolipids in processes that control diverse cellular responses. Furthermore, the increase 
of free sphinganine is a biomarker for farm animals to evaluate the exposure to toxic levels 
of fumonisins. In animals, consumption of FB1 increases the levels of free sphinganine (Sa) 
in liver, kidney, serum and/or urine (Enongene et al., 2000) which is thought to be largely 
responsible for the toxicity and carcinogenicity of this mycotoxin (Yoo et al., 1992; Humpf 
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et al., 1998). Accumulation of sphingoid bases and the increasing Sa:So ratio after fumonisins 
exposure have been demonstrated in multiple studies (Enongene et al., 2000).  
1.3.5 Studies in animals and main target organs 
It is proved that fumonisins have diverse effects on animals (localisation of lesions, target 
organs), according to sex, strain, and species (FAO/WHO, 2012). Even if certain organs 
appear to be constantly affected to a greater or lesser degree, the main target organ are 
different in each species: the brain in horses, liver and heart in rats, the lung in pigs, the kidney 
and liver in sheep (Kriek et al., 1981). In particular, FB1 is toxic to the liver and kidney in all 
species, causing apoptosis and subsequent mitosis in the affected tissue. FB1 is toxic to the 
cardiovascular system in pigs and horses as well (Voss et al., 2007). Anyway is noted that 
nutritional factors, such as folate and antioxidants, modulate fumonisin toxicity. 
Horses 
Fumonisin B1, produced by F. moniliforme  is the cause of equine leukoencephalomalacia 
(ELEM) when repeated injections of 125 µg/kg BW induced brain and liver lesions (Marasas 
et al., 1988). Symptoms are ataxia, head pressing, paralysis of the lips and tongue and 
convulsion. At the necroscopy, focal malacia and liquefaction of cerebral white matter with 
peripheral haemorrhage are found. The mechanism by which fumonisins cause this disease 
are apparently linked to their ability to inhibit sphingolipid synthesis (CAST, 2003). The rate 
of mortality is near the 100%, makes horses one of  the most sensitive specie to fumonisins 
(Voss et al., 2011).  
Pigs 
Another sensitive farm animal is swine. The first study reported severe toxicosis, called  
porcine pulmonary edema (PPE) was (Kriek et al., 1981). In 1989 in the Midwestern and 
Southwestern parts of the United States thousands of pigs died from PPE after ingesting corn 
contaminated with fumonisin B1 (from 155 to 92 mg/kg). A hot dry summer in those areas of 
United States were responsible for the very high levels of fumonisin. Physiologically the two 
main causes of pulmonary edema are left ventricular failure, which increases pulmonary 
capillary hydrostatic pressure, and increased vascular permeability after injuries to the 
alveolar capillary endothelium or alveolar epithelium (Colvin et al., 1993). To develop PPE, 
pigs have to be fed with feed containing concentrations of FB1 ≥ 92 ppm or ≥ 16 mg/kg 
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BW/day. Equally, lethal PPE occurs within 7 days after daily intravenous administration of 
FB1 (Harrison et al., 1990). In addition, hepatic lesions consisting in apoptosis, necrosis and 
hepatocyte proliferation are observed.  
The pharmacokinetics of FB1 in swine indicates a poor bioavailability (3-6% of absorption). 
Fumonisin are firstly excreted in the faeces (60%) and secondly in the urine (20%) with 
enterohepatic recycling. After 72 hours from the administration of fumonisin residues are 
greatest in liver than kidney, large intestine, brain, lung, heart, spleen.  
 Low doses of fumonisin B1 at 0.5 mg/kg BW/day can reportedly increase susceptibility of 
pigs to pathogenic E. coli strains, Pseudomonas aeruginosa and Pasteurella multocida. 
Fumonisins are also known to increase the susceptibility of pigs to Porcine Reproductive and 
Respiratory Syndrome. Another specific effect of fumonisin in swine is the accumulation of 
membranous material in pulmonary capillary endothelial cells. Moreover fumonisin induced 
cardiovascular changes due to the inhibition of L-type calcium channels by increased 
sphingosine and/or sphinganine concentration (Colvin et al., 1993). Because of the similarity 
between swine and human cardiovascular system, the mechanism of fumonisin toxicosis in 
swine must be studied to permit assessment of its potential toxicity in humans. In fact, it is 
well known that the association between high level of fumonisin ingestion and esophageal 
cancer caused by neural-tube defects linked to fumonisin-induced folate deficiency (CAST, 
2003). 
Ruminants 
Ruminants are less sensitive to mycotoxins, which may be explained by the fact that 
fumonisin is unmetabolized in the digestive tract and excreted in the faeces. However, the 
production of milk and beef meat, reproduction and growth can be altered if animals are fed 
with mycotoxin-contaminated feed for a long period (Pierron et al., 2016; Hussein and Brasel, 
2001). 
Rats 
Fumonisins have been shown to act as liver cancer promoters in rats. Gelderblom et al. (1991) 
found hepatocarcinomas in male rats fed 50 mg of fumonisins B1/ kg for 26 months. After 
using purified (˃90%) FB1 and a single dose of 0, 5, 50, or 500 µg/kg BW in male Wistar 
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rats, a significant increase in the number of apoptotic cells in liver were observed after 24 
hours at 5 µg/kg BW. At 50 and 500 µg/kg BW the number of apoptotic cells in liver was 
significantly increased from 4 to 48 hours after treatment, and necrotic cells were observed at 
all dose levels and times. This implies that the single-dose NOAEL for apoptosis in male 
Wistar rat liver would be below 5 µg/kg BW.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
26 
 
2. Experimental Part 
2.1 Aim of the study 
The main objective of the study was to test the effects of 20 mg/kg feed dose of FB1 mycotoxin 
on the lipid composition of growing piglets, following a 10-day exposure. The basic 
hypothesis was that via the ceramide synthesis blockade FB1 might induce a disturbance in 
the fatty acid metabolism of the liver and the kidney. This has been approached by analysing 
the two most abundant and important lipids fractions’ fatty acid profile, namely phospholipids 
and triglycerides.  
2.2 Material and Methods 
2.2.1 Experimental Plan 
To investigate the short-term effect of Fumonisins B1 on the lipid (fatty acids) metabolism in 
swine, a 10 days long experiment was set up by the University of Kaposvàr (Hungary). The 
experiment was set at the Agricultural Department of the University in an experimental 
piggery area. The target organs were: liver and kidneys. 
Fourteen weaned barrows of the same genotype were used in the experiment. The animals 
were placed in metabolic cages (80x80cm), the water was given ad libitum and the 
temperature of the room was in accordance to the needs of the weaned piglets. The feed was 
given twice a day, at 8:00 a.m. and 15:00 p.m., in equal portions. The feed that was not 
consumed was measured back at the end of the second ration. Seven days after the beginning 
of the experiment, the piglets were weighed (average=11.44 kg; DS=1.29 kg). During the first 
twelve days, the total amount of feed offered was 400 g/day/pig and it did not contain 
mycotoxins. After this adaption period, the amount of the feed was raised to 500 g/day/pig 
for 4 days still without mycotoxins. The feed during this period was a basic ration with a 
composition corresponding to their age (Platinum-PF Starter piglet feed mix) (Tables 7, 8). 
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Table 7: Tests carried out with Weende Analysis 
Laboratory samples 
number 
Examined Parameters Standard Methods 
170627 
Dry matter MSZ ISO 6496:2001 
Crude protein 
MSZ EN ISO 5983-
2:2009 
Ether extract MSZ 6830-19:1979 
Crude fibre 152/2009/EK III/I 
Crude ash MSZ 5984:1992 
 
Table 8: Test results (% as is) 
Sample 
name 
Laboratory 
samples 
number 
Water Protein Fat 
Crude 
fibre 
Ash 
Swine 170627 9.2 17.9 5.3 2.9 4.6 
 
On the seventeenth day, the mycotoxin administration started and the animals were divided 
in two groups: control group n=7 and experimental group n=7. The duration of the trial was 
ten days. During this period, the experimental group was fed with the same fodder but 20 
mg/kg feed of FB1 was added to provide a 10 mg of FB1 daily intake. At the end of the 
experiment the animal were weighed to note some differences in the body weight (Table 9). 
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Table 9: Weight of pigs (Kg) 
Pigs Live Weight (kg) Weight gain (kg) 
 21/03/2017 09/04/2017   
1 /C 10.1 14 3.9 
2 /C 11.2 15.3 4.1 
3 /C 13.1 18 4.9 
4 /C 10.2 14.8 4.6 
5 /C 12.6 18.4 5.8 
6 /C 10 12.6 2.6 
7 /C 13.1 18.5 5.4 
8 /T 13 18 5 
9/T 9.6 13.4 3.8 
10 /T 12.8 17.8 5 
11 /T 10.7 16 5.3 
 12 /T 10.4 14 3.6 
13 /T 11.7 15 3.3 
14 /T 11.7 16.6 4.9 
Average 11.44 ± 1.29 15.89 ± 2.01 4.44 ± 0.91 
 
At the same time, the piglets were used in a Ph.D. thesis to analyse the effect of Fumonisin 
B1 on the caecal microbiota.    
After the dosing test, the piglets were killed by exsanguination after sedation.  
2.2.2 Determination of mycotoxin content in feed 
Toxin production 
Fusarium verticillioides NRRL 20960 (MRC 826) fungal culture (7 days old) was grown on 
0.5 strength potato dextrose agar (PDA; Chemika-Biochemica, Basle, Switzerland). Agar 
discs (5 mm) were prepared with cork borer (Boekel Scientifica, Pennsylvania, USA), which 
were then stored at 10 ºC in darkness in test tubes containing sterile distilled water (10 
discs/10 ml).  
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For toxin production, maize (40 g) was soaked in distilled water (40 ml) at room temperature 
for 1 hour in Erlenmeyer flasks (500 ml), closed with cotton wool plugs. This was followed 
by the addition of the inoculated agar discs (10 agar discs per flask) to the two-times 
autoclaved (20 min.) matrix. The cultures were then stored and incubated at 24 ºC for 3 weeks, 
respectively. The flasks were shaken twice every day during the first week of incubation. 
When the incubation time was complete the fungus-infected cereal was dried at room 
temperature and ground.  
LC-MS Analysis 
LC-MS analysis was performed by a Shimadzu Prominence UFLC separation system 
equipped with a LC-MS-2020 single quadrupole (ultra-fast) liquid chromatograph mass 
spectrometer (Shimadzu, Kyoto, Japan) with electrospray source.  
Samples were analysed on a Phenomenex Kinetex 2.6μ X- C18 column (100 mm × 2.1 mm). 
The column temperature was set to 50ºC, the flow rate was 0.3 ml/minute and the injection 
volume was 1 μl. The gradient elution was performed using double distilled water (eluent A) 
and methanol (eluent B), both acidified with 0.2% formic acid; initial condition at 60% A, 0-
2 minutes isocratic step, 2-6 minutes linear gradient to 70% B, 6-13 minutes linear gradient 
to 100% B, 13-15 minutes isocratic step at 40% B. Total analysis was 15 minutes. MS 
parameters: source block temperature 90º C; desolvation temperature 250º C; heat block 
temperature 200º C; drying gas flow 15.0 l/minute. Detection was performed using SIM 
mode. 
The mass spectrometer was operating in the selective ion monitoring mode, at m/z 722.4 for 
FB1. 
Calibration curves using FB1 standard in the range of 10-500 μg/kg were prepared. The limit 
of detection (LOD) for FB1 was 3 μg/kg, while the limit of quantification was (LOQ) 10 
μg/kg. 
The homogenized fungal cultures contained FB1 at concentration of 916 mg/kg (FB2: 185 and 
FB3 79 mg/kg).  
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2.2.3 Blood and Tissue sampling  
Blood sampling was performed according to the method of Shanmugasundaram et al. (1992).  
Fresh venous blood was sampled into heparinized (20 IU/mL whole blood) tubes (lithium 
salt) and was centrifuged for 10 minutes at 1,000 g, at the end of the tenth day. Plasma and 
the buffy coat (mix of platelet and leukocytes) were removed and the erythrocyte bulk was 
washed three times with a common biological buffer TRIS-HCl (0.1M; pH=7.4) solution at 
4°C. This isotonic solution permitted to remove the remaining plasma and adhered surface 
proteins. After each wash, the buffy coat and the washing medium were siphoned. Subsequent 
of the third wash, hypotonic TRIS-HCl (15mM; pH=7.4) solution was used to make the red 
blood cell porously. This ice-cold and more diluted buffer allowed the haemoglobin to enter 
the solution. Erythrocyte lysate (cell membrane pellet) was centrifuged at 10000 g for 10 
minutes at 4°C for seven times. The supernatant contained the haemoglobin, was discarded 
after each centrifugation. After the washing medium was colourless, it was washed the last 
time with distilled water.  
Stored at -20°C. 
After exsanguinations the liver, kidney, spleen, lung and heart were immediately dissected 
and weighed. (Table10) 
All samples were stored at -20°C until analysis. 
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Table 10: Weight of the organs (g) 
Animal Liver (g) Kidney (g) Spleen (g) Lung (g) Heart (g) 
8 /T 390.3 69.4 47.1 197.3 110.8 
9 /T 312 75.4 32.5 162.3 103.1 
10 /T 4431 85.9 35.7 267 115.2 
11 /T 349.1 85.4 34.7 174.6 123.4 
12 /T 273.3 73.7 31.6 155.4 88.2 
13 /T 350 75.7 34.4 172.7 93 
14 /T 392.8 1033 36.7 195.2 112.5 
1 /C 255.8 79.3 43.2 242 108.3 
2 /C 329.8 96.9 37.3 180.7 87.4 
3 /C 393.3 84.6 38 220.8 118 
4 /C 299.9 90.8 29.6 156 85.7 
5 /C 475 96.5 40.6 205.8 97.3 
6 /C 322.6 70.7 39.6 155 82 
7 /C 439 77.6 40 224.2 115.8 
 
2.2.4 Total lipid extractions: liver, kidney and blood cell membranes  
After slaughter, small pieces from liver and kidney were taken and stored at - 20°C (Figure 
4). For the determination of total lipid content in these animal tissues and in the red blood cell 
membrane, the method of Folch et al. (1957) was used. The present method has the advantage 
to be simple and to decrease the losses of lipids due to the washing process.  
To start the lipid extraction small tissue pieces (0.2 g) were cut. The portion was placed into 
a 15ml centrifuge plastic tube and 5 ml of solvent were added as to obtain an excess of 25-
fold. To determine the total membrane lipids, 50 µl of washed red blood cell membrane were 
taken. The solvent was a 2:1 chloroform/methanol (v/v) mixture (chl/meth) + 100 mg/L 
butylated hydroxytoluene (BHT) which is an antioxidant and prevents the fatty acid (FA) 
oxidation. Chloroform acts as an extractor of the neutral lipids (non-polar) while the methanol 
extracts the polar lipids like the phospholipids. 
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Figure 4: Samples of kidney and liver tissues 
 
Solvent and tissues were homogenized with ULTRA-TURRAX (IKA T25 digital) (Figure 5). 
After each sample, the grinder was immersed into the same solution of chl/meth and any 
residue of tissues were removed.  
 
Figure 5: The figure shows the ULTRA-TURRAX (IKA T25 digital) machine 
 
The homogenate was filtered through a fat-free filter paper (black code; quantitative type; 
MN 640 W; diameter 125 mm; retention pore 12-15 µm). To insure a complete removal of 
33 
 
the homogenate the tube was washed with an additive of 2 ml of chloroform/methanol 
(chl/meth) + BHT.  
When the liquid dripped and the dry matter was retained in the filter, 2.5 ml of physiological 
saline (0.9%) were added with a pipette into the tube. Physiological saline allows the 
separation of the two different phases: the upper phase contains all the non-lipid substances; 
the lower phase contains all the lipids. The acidic lipids are present in the upper phase in 
dissociated forms and in the lower phase in un-dissociated forms. The addition of mineral salt 
decreases the dissociation of the acidic lipids by a mass action effect with a consequent shift 
of lipids to the lower phase (Folch et al., 1957). 
In order to achieve complete separation the samples were centrifuged for 2 min at 2000 g. 
The upper layer (40% of the total volume of the system) was composed by water and 
methanol, while the lower layer (60% of the total volume of the system) contained the 
chloroform and the lipid fraction. Between the two layers a thin interface layer was formed 
which was consisted of the protein content of the tissues (Figure 6).  
 
Figure 6: In the figure is possible to see the separation of the two layers 
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The non-lipid fraction along with the protein fraction were aspirated with a pipette and were 
discarded. 
The lipid fraction was poured into a glass flask, previously weighed, and a wash with the 
solution (1-2 ml) permitted the removal of the lipids.  
The flask was posed in a rotary-evaporation (62 °C; 90 r.p.m.) (Figure 7). When the flask 
became dry, an air stream was applied in order to eliminate any remaining traces of solvent.  
 
Figure 7: In the figure is possible to see the separation of the two layers 
 
The flasks were weighed after they cooled down. The difference in terms of weight was 
represented by the total lipid content.  
Whit a pipette 3 ml of the solvent mixture the flask was washed to permit the transfer of the 
lipids to glass vials, than samples were stored in the fridge at -20°C 
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2.2.5 Separation of lipid fractions by Silicagel Column Chromatography  
The general procedures for the separation of lipids fractions by Cyberlipid Center was 
followed (http://www.cyberlipid.org/cyberlip/home0001.htm). A small piece of cotton was 
placed at the bottom of a glass Pasteur pipettes in order to keep silicagel in the tube as a filter 
(Figure 8).  
 
Figure 8: Silicagel Column Chromatography 
 
Before starting the procedure 100 mg of silica gel were weighed into a micro centrifuged tube. 
The silica gel and chloroform were mixed and were transferred into the column in order to 
form a layer. This separation was based on differences in degree of adsorption of lipid 
components into a solid phase. The solid phase was polar and so the lipids were eluted by 
increasing polarity solvents. 
According with to measurement obtained from the total lipid extraction expressed in mg, a 
proportion was made (3 mg: 1 ml= (known weight) mg: X ml). This calculation permitted to 
know how many ml should be put in the column for each sample. The lipid sample was 
transferred in the glass column to the top of the gel. When the solvent (chl/meth) dripped the 
separation of the lipid fraction started. 
36 
 
Previously labelled and weighed plastic tubes were positioned under the columns. The first 
fraction was obtained after adding 3 ml of chloroform in each column in order to elute the 
triglycerides (neutral lipids in general e.g. fatty acids, hydrocarbons, sterols, waxes, etc.). 
After that first sample was drained, the second fraction was obtained by adding 4.5 ml of 
acetone/methanol (9/1 vol/vol) that allowed the extraction of sphingolipids (glycolipids and 
ceramide). The fraction of the phospholipids, the third one, was eluted by adding 3 ml of 
methanol. Using this method, three different fractions of lipids from liver and kidney were 
obtained. After separation samples were stored at -20°C. 
2.2.6 Lipids transmethylation for Gas Chromatography 
The triglycerides, the total phospholipids and the total membrane lipids were transmethylated 
with a base-catalysed sodium-methoxide method of Christie (1982). This method (methyl 
esterification) was necessary to make the fatty acids volatile and “readable” by Gas 
Chromatography. 
The fractions were moved in a previously weighed flask. The fractions were evaporated using 
a rotary-evaporator machine (62°C; 90 r.p.m.). After the cooling, the flasks were weighed 
again. The difference in terms of weight represented the triglycerides, phospholipids and red 
blood cells.  
The obtained fractions were dissolved in 1.1 ml of ether (medium). The solution was briefly 
agitated to ensure the mixing. The solution was put into a glass tube with a pipette and 20 µl 
of methyl-acetate were added to avoid the hydrolysis of fatty acids. Then 20 µl of sodium 
methylate (NaOCH3 1M sol. in methanol) were summed. The solution immediately became 
cloudy due to the precipitation of the sodium-glycerol derivatives. Sodium methylate was the 
donor of the methyl group during the process of methyl esterification of the fatty acids. The 
methyl esterification was necessary to make the fatty acid volatile and readable by Gas 
Chromatography. 
After 5 minutes at room temperature, 30 µl of oxalic acid in ether were added in order to stop 
the reaction. The mixture was centrifuged for 2 minutes at 1500 g to precipitate sodium 
oxalate (sodium-oxalate precipitate). 
The ether was removed by evaporation under an air stream but the fatty acid methyl esters 
remained in the tube because their temperature of evaporation is around 260°C (Figure 9).  
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Figure 9: In the figure is possible to see the opaque layer composed by FA methyl esters 
 
Approximately 200 mg of sodium sulphate (Na2SO4) and 300 µl of hexane were then added 
to the sample. The sodium sulphate needed to eliminate possible traces of water from the 
sample. To permit the precipitation of the sodium oxalate and the sodium sulphate the samples 
were running in the centrifuge for 2 minutes at 1500 g. The last step was aspiration of the 
hexane in which the fatty acid methyl esters were dissolved. 
Stored at -20°C. 
2.2.7 Thin Layer Chromatography  
The complex lipids which were extracted from the liver and kidneys were separated to 
perform the thin-layer chromatography (TLC) using the protocol of Skipski et al. (1964). This 
method permitted the qualitative separation of phospholipids, obtaining the determination of 
phosphatidylcholine (PC), phosphatidylinositol (PI) and phosphatidylserine (PS). 
TLC silica gel G60 plates were signed with a line made by a pencil. Following this line, the 
samples (50 µl or less) were applied with a micropipette. Repeating for three times to have a 
high amount of lipids. 
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The silicagel is polar and it represented the stationary phase. Chloroform/methanol/water 
65:35:7 (vol/vol/vol) was the mobile phase and it was poured in a closed elution chamber (the 
amount of the solvent needed to be under the start line of the plate).  
The plate was put into the TL development chamber and the moving phase started following 
the principle of capillary reaction (moving phase) (Figure 10). After the samples were eluted 
by the solvent, the plate was removed from the chamber and it was left to dry for some minutes 
at room temperature. 
 
Figure 10: TLC development chamber 
 
The plate was sprayed Primuline (5 mg/100ml). The dye permitted to visualise the spots of 
the different phospholipids under a UV lamp (346 nm). The separations of the lipids happened 
due to the different polarity of the components (Figure 11).  
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Figure 11: Spots of phospholipids fractions (PC, PI, PS) 
 
                                                          Polarity: PC˃PI˃PS 
Each fraction was removed from the plate and put in a labelled glass tube and 3 ml of ether 
were added. The solution was centrifuged for 2 min at 1500 g. The supernatant was aspirated 
with a pipette and was transferred into a clean glass tube previously labelled. Subsequently 
20 ml of methyl-acetone and 20 ml of sodium methylate were added. After five minutes 30 
ml of oxalic acid were added to stop the reaction.  
The phosphatidylcholine (PC) fraction on the thin layer was confirmed by a PC standard 
which was purchased Sigma-Aldrich (Schnelldorf, Germany).  
The solvent was evaporated under an air stream and 200 mg of sodium sulphate were put in 
the glass tube with 300 µl of hexane.  
The samples were centrifuged for 2 minutes at 1500 g and the supernatant was transferred 
and put in a small glass vials with a pipette, for subsequent GC analysis. Until than, the 
samples were stored at -20°C. 
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2.3 Ethical Statement  
Experimental protocol was authorized by the Food Chain Safety and Animal Health 
Directorate of the Somogy County Agricultural Office, under allowance number: XV-I-
31/1509-5/2012. 
 
2.4 Statistical analysis 
To determine whether statistical differences among groups an independent samples t-test was 
used, using IBM SPSS Statistics Data Editor.  
The level of significance was set to P˂0.05 
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3. Results 
3.1 Productive parameters and Organ weights 
During the ten days of the trial, animals were observed to notice changings in their behaviour. 
The pigs fed with the experimental diet did not show clinical signs of disease. The 
consumption of the contaminated feed was regular during the experiment and no feed refusal 
was noted. Only a single animal from the toxin group, after four days of treatment, 
demostrated to be quiet and inactive.  
In terms of productive parameters, no significance difference was observed between the two 
groups. There was no statistical difference in terms of body weight gain between the control 
and the toxic groups (Table 11).  
A comparison of the organ weight values (group means) was made between the two groups. 
No statistical difference has been induced by the mycotoxin treatment. Kidney, liver and lungs 
weights have been analysed as shown in table below (Table 11).  
 
Table 11: T-test of liver weight (g), kidney weight (g), lungs weight (g) and body weight             
gain (kg) 
  T-test   
 Control FB1 Significance 
  Mean ± SD Mean ± SD  
 
Kidney 
weight (g) 
85.2 ± 10.0 81.3 ± 11.45 n.s. 
 
Liver 
weight (g) 
359.3 ± 78.9 358.6 ± 56.16 n.s. 
 
Lungs 
weight (g) 
197.8 ± 34.43 189.2 ± 37.65 n.s. 
 
Body 
Weight 
Gain (kg) 
 
4.5 ± 1.06 4.4 ± 0.81 n.s. 
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3.2 Kidney phospholipids 
Kidney total phospholipids were analyzed (Table 12). As noted in the following table alpha-
linolenic acid (C18:3 n-3) decrease in the mycotoxin treated group. Behenic acid (C22:0) and 
lignocerid acid (C24:0) had a similar reduction in the toxin-treated  group. The average chain 
length (ACL) and the total saturated fatty acids (SFA) were the only that provided an increase 
in the toxin treated group. 
Table 12: The FA profile (% of total FAME) of the kidney phospholipids (data represent 
means and SD of 7 individuals/group) 
  Kidney phospholipids   
Group Control FB1 Significance 
  Mean ± SD Mean ± SD  
C14:0 0.18 ± 0.02 0.17 ± 0.04 n.s. 
C15:0 0.11 ± 0.03 0.11 ± 0.03 n.s. 
C16:0 17.3 ± 1.25 16.2 ± 1.04 n.s. 
C16:1n-7 0.28 ± 0.05 0.27 ± 0.08 n.s. 
C17:0 0.39 ± 0.07 0.48 ± 0.16 n.s. 
C18:0 22.3 ± 0.33 22.1 ± 1.00 n.s. 
C18:1n-9 9.77 ± 1.03 10.2 ± 1.41 n.s. 
C18:2n-6 22.0 ± 1.13 21.0 ± 1.24 n.s. 
C18:3n-6 0.14 ± 0.06 0.15 ± 0.05 n.s. 
C18:3n-3 0.71 ± 0.06 0.62 ± 0.10 0.054 
C20:0 0.12 ± 0.02 0.10 ± 0.01 n.s. 
C20:1n-9 0.19 ± 0.05 0.22 ± 0.06 n.s. 
C20:2n-7 0.87 ± 0.16 0.86 ± 0.13 n.s. 
C20:3n-6 2.00 ± 0.51 2.54 ± 0.92 n.s. 
C20:4n-6 16.6 ± 0.96 17.9 ± 2.10 n.s. 
C20:3n-3 0.31 ± 0.08 0.28 ± 0.05 n.s. 
C20:5n-3 5.09 ± 1.06 5.05 ± 1.11 n.s. 
C22:0 0.08 ± 0.01 0.05 ± 0.01 0.0001 
C22:5n-3 1.50 ± 0.33 1.44 ± 0.12 n.s. 
C24:0 0.16 ± 0.02 0.12 ± 0.02 0.002 
SFA 40.6 ± 0.77 39.8 ± 0.87 0.043 
MUFA 10.2 ± 1.12 10.7 ± 1.54 n.s. 
PUFA 49.2 ± 1.89 49.8 ± 1.58 n.s. 
n-6 40.7 ± 1.42 41.7 ± 1.05 n.s. 
n-3 7.62 ± 0.98 7.39 ± 1.26 n.s. 
n-6 / n-3 5.42 ± 0.75 5.78 ± 0.99 n.s. 
Odd chains 0.50 ± 0.09 0.59 ± 0.19 n.s. 
unsat. index 236.9 ± 11.38 245.0 ± 12.28 n.s. 
ACL 18.2 ± 0.05 18.3 ± 0.06 0.052 
 
43 
 
3.3 Kidney triglycerides 
Kidney triglyceride fatty acid profile was non-responsive towards the FB1 treatment applied 
(Table 13). 
Table 13: The FA profile (% of total FAME) of the kidney triglycerides (data represent means 
and SD of 7 individuals/group) 
  Kidney triglycerides   
Group Control FB1 Significance 
  Mean ± SD Mean ± SD  
C14:0 0.56 ± 0.10 0.63 ± 0.30 n.s. 
C15:0 0.12 ± 0.03 0.11 ± 0.02 n.s. 
C16:0 13.3 ± 2.77 13.9 ± 4.01 n.s. 
C16:1n-7 0.47 ± 0.13 0.96 ± 1.07 n.s. 
C17:0 0.29 ± 0.05 0.30 ± 0.04 n.s. 
C18:0 16.3 ± 1.56 14.1 ± 3.33 n.s. 
C18:1n-9 9.93 ± 1.84 14.0 ± 8.09 n.s. 
C18:2n-6 26.9 ± 2.90 28.9 ± 2.30 n.s. 
C18:3n-6 0.13 ± 0.08 0.15 ± 0.06 n.s. 
C18:3n-3 1.07 ± 0.21 1.25 ± 0.29 n.s. 
C20:0 0.24 ± 0.05 0.20 ± 0.08 n.s. 
C20:1n-9 0.32 ± 0.09 0.40 ± 0.14 n.s. 
C20:2n-7 2.03 ± 0.32 1.89 ± 0.46 n.s. 
C20:3n-6 1.45 ± 0.44 1.66 ± 0.76 n.s. 
C20:4n-6 18.4 ± 2.51 14.8 ± 6.83 n.s. 
C20:3n-3 1.02 ± 0.21 0.93 ± 0.28 n.s. 
C20:5n-3 5.38 ± 1.07 4.21 ± 2.29 n.s. 
C22:0 0.13 ± 0.04 0.10 ± 0.08 n.s. 
C22:5n-3 1.66 ± 0.24 1.37 ± 0.48 n.s. 
C24:0 0.22 ± 0.07 0.17 ± 0.10 n.s. 
SFA 31.1 ± 2.98 29.5 ± 1.33 n.s. 
MUFA 10.7 ± 2.00 15.4 ± 9.27 n.s. 
PUFA 58.0 ± 4.64 55.1 ± 10.1 n.s. 
n-6 46.9 ± 3.81 45.5 ± 7.28 n.s. 
n-3 9.13 ± 1.17 7.75 ± 2.77 n.s. 
n-6 / n-3 5.19 ± 0.60 6.46 ± 1.96 n.s. 
Odd chains 0.41 ± 0.08 0.41 ± 0.04 n.s. 
unsat. index 267.7 ± 19.5 241.5 ± 59.45 n.s. 
ACL 18.3 ± 0.11 18.2 ± 0.33 n.s. 
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3.4 Liver phospholipids 
In the liver phospholipid fatty acid profile it was determine by GC (Table 14). Alpha-linolenic 
acid (C18:3 n-3) proportion decreased as the decosapentaenoic acid (C22:5 n-3) decreased as 
well. An increase was found in the proportion of arachidonic acid (C20:4 n-6). The total 
saturation level decreased. The total level of omega-3 fatty acids (FAs) decreased 
significantly. An increasing n-6 / n-3 FA ratio was detected. 
Table 14: The FA profile (% of total FAME) of the liver phospholipids (data represent means 
and SD of 7 individuals/group) 
  Liver phospholipids   
Group Control FB1 Significance 
  Mean ± SD Mean ± SD   
C14:0 0.15 ± 0.03 0.17 ± 0.03 n.s. 
C15:0 0.14 ± 0.07 0.18 ± 0.11 n.s. 
C16:0 16.9 ± 0.68 16.2 ± 0.91 n.s. 
C16:1n-7 0.32 ± 0.07 0.41 ± 0.17 n.s. 
C17:0 0.79 ± 0.25 1.16 ± 0.68 n.s. 
C18:0 31.7 ± 1.03 31.6 ± 1.95 n.s. 
C18:1n-9 6.27 ± 0.56 6.80 ± 1.19 n.s. 
C18:2n-6 22.5 ± 1.16 22.1 ± 0.80 n.s. 
C18:3n-6 0.15 ± 0.03 0.19 ± 0.05 n.s. 
C18:3n-3 0.23 ± 0.05 0.19 ± 0.04 0.082 
C20:0 0.08 ± 0.01 0.09 ± 0.02 n.s. 
C20:1n-9 0.13 ± 0.02 0.13 ± 0.02 n.s. 
C20:2n-7 0.72 ± 0.09 0.67 ± 0.07 n.s. 
C20:3n-6 1.46 ± 0.39 1.38 ± 0.28 n.s. 
C20:4n-6 13.2 ± 1.47 14.3 ± 0.40 0.077 
C20:3n-3 0.15 ± 0.04 0.13 ± 0.02 n.s. 
C20:5n-3 1.47 ± 0.60 1.47 ± 0.35 n.s. 
C22:0 0.03 ± 0.00 0.04 ± 0.01 n.s. 
C22:5n-3 3.32 ± 0.14 2.54 ± 0.33 0.0001 
C24:0 0.38 ± 0.04 0.28 ± 0.05 0.002 
SFA 50.1 ± 0.74 49.7 ± 1.10 0.045 
MUFA 6.7 ± 0.61 7.3 ± 1.34 n.s. 
PUFA 43.2 ± 1.00 43 ± 0.94 n.s. 
n-6 37.2 ± 0.88 37.9 ± 0.64 n.s. 
n-3 5.17 ± 0.63 4.32 ± 0.36 0.009 
n-6 / n-3 7.29 ± 0.82 8.83 ± 0.67 0.002 
Odd chains 0.93 ± 0.31 1.33 ± 0.79 n.s. 
unsat. index 189.8 ± 8.75 187.9 ± 3.97 n.s. 
ACL 18.1 ± 0.04 18.1 ± 0.04 n.s. 
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3.5 Liver triglycerides  
In contrast to the non-responsive liver phospholipids, the liver triglycerides (Table 14) 
provided slight compositional alterations. The proportion of stearic acid (C18:0) increased in 
the toxin treated group, as well as the proportion of arachidonic acid (C20:4 n-6). A slight 
decrease was found for lignoceric acid (C24:0). The total n-6 / n-3 fatty acids increased. 
Table 15: The FA profile (% of total FAME) of the liver triglycerides (data represent means 
and SD of 7 individuals/group) 
  Liver triglycerides   
Group Control FB1  Significance 
  Mean ± SD Mean ± SD   
C12:0 0.04 ± 0.01 0.08 ± 0.12 n.s. 
C14:0 0.38 ± 0.15 0.28 ± 0.09 n.s. 
C15:0 0.11 ± 0.05 0.13 ± 0.06 n.s. 
C16:0 13.5 ± 2.30 12.1 ± 0.75 n.s. 
C16:1n-7 0.61 ± 0.32 0.41 ± 0.15 n.s. 
C17:0 0.69 ± 0.24 0.95 ± 0.65 n.s. 
C18:0 29.3 ± 2.09 31.2 ± 1.39 0.067 
C18:1n-9 8.96 ± 2.98 7.20 ± 0.95 n.s. 
C18:2n-6 20.3 ± 2.17 19.6 ± 0.88 n.s. 
C18:3n-6 0.16 ± 0.09 0.20 ± 0.05 n.s. 
C18:3n-3 0.61 ± 0.32 0.44 ± 0.14 n.s. 
C20:0 0.14 ± 0.07 0.12 ± 0.01 n.s. 
C20:1n-9 0.16 ± 0.12 0.21 ± 0.08 n.s. 
C20:2n-7 0.77 ± 0.12 0.70 ± 0.05 n.s. 
C20:3n-6 1.42 ± 0.43 1.45 ± 0.28 n.s. 
C20:4n-6 17.1 ± 1.91 19.5 ± 1.16 0.015 
C20:3n-3 0.23 ± 0.07 0.21 ± 0.05 n.s. 
C20:5n-3 1.58 ± 0.64 1.68 ± 0.29 n.s. 
C22:0 0.11 ± 0.09 0.06 ± 0.02 n.s. 
C22:5n-3 3.45 ± 0.39 3.15 ± 0.28 n.s. 
C24:0 0.42 ± 0.08 0.36 ± 0.04 0.072 
SFA 44.7 ± 2.58 45.3 ± 1.29 n.s. 
MUFA 9.7 ± 3.38 7.8 ± 1.14 n.s. 
PUFA 45.6 ± 4.68 46.9 ± 1.13 n.s. 
n-6 38.9 ± 3.72 40.7 ± 0.97 n.s. 
n-3 5.87 ± 1.09 5.48 ± 0.35 n.s. 
n-6 / n-3 6.74 ± 0.79 7.46 ± 0.47 0.063 
odd chains 0.80 ± 0.28 1.08 ± 0.70 n.s. 
unsat. index 216.6 ± 20.29 225.0 ± 5.89 n.s. 
ACL 18.3 ± 0.11 18.3 ± 0.04 n.s. 
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4. Discussion  
Fumonisin B1 has practically no effect on the kidney weight. This is rather interesting, since 
it is known that FB1 is generally weakly absorbed (4-6% of the total dietary intake), but once 
entering the circulation, its elimination happens via the renal filtration (Fodor et al., 2008). In 
the cited study, 45 mg/kg mycotoxin dose was applied for 10 days, and this did not induce 
any alteration in the renal weight of weaned piglets. 
The weight alteration of liver was based on the hypothesis that FB1 is providing slight 
hepatotoxicity in rodents. This effect is mainly attained via immediately impairing the 
integrity membrane phospholipids, even before the enzymatic antioxidant defence is activated 
(Szabó et al., 2016). It seems that piglets are much less sensitive towards this effect, most 
probably due to the lack of coprophagy, characteristic for the rodents. Anyway, in a study 
conducted by Abel and Gelderblom (1998) in which rats were fed with a dietary levels of FB1 
of 10, 50, 100, 250, 500 mg/kg diet for 21 days, the relative liver weight of the first three 
groups did not have significant effects. Only the relative liver weight of the 250 mg FB1/kg 
diet group had a significantly reduction.  
We similarly did not detect any difference in the weight of spleen and heart between groups, 
but detailed analysis of this dataset is not reasoned, since immunotoxic or sacolemma 
damaging effects have never been reported for FB1. Alteration in terms of mycotoxin feeding 
has been expected since pulmonary edema (interstitial) is a differentia specifica of FB1 
toxicosis of piglets (Kriek et al., 1981). Since FB1 has a rather strong effects as well on the 
cation exchange in mammals (Szabò et al., 2014), edema development has been hypothesized, 
but again, not proven.  
Our results are in agreement with the study of  Andretta et al. (2012), which asserts that 
fumonisins do not influence the weight of kidneys and spleen, but it increased the relative 
weight of liver, heart and lungs. Probably in this study, we did not notice the increase in 
weight of liver and heart because of the short-term and low-dose trial. Thus, summarized, we 
hypothesize that FB1 at a concentration of 20 mg/kg of feed for weaned piglets may affect 
membrane integrity to a slight extent, but does not have major effects, at least not at a level 
that may exert harmful effects on the organs in study. 
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Similar results of productive parameters were reported by  Riley and Voss (2006) in a study 
with rats. Rats were fed diets contaminated with fumonisins at concentrations 1.1, 13.5 and 
88.6 mg/kg of feed for 10 days. After the trial no significant statistically difference was 
observed in body weight or feed consumption among groups. Dilkin et al. (2003) conducted 
an experiment with crossbreed piglets that were exposed to dietary FB1 at concentrations of 
10 mg/kg or 30 mg/kg of feed for 28 days. In this case, a statistically significant difference in 
feed consumption and weight gain were noticed in the group fed the 30 mg of FB1/kg diet 
compared with the 10 mg of FB1/kg diet and can be attributed to the longer exposure period. 
It should be highlighted that one of the animals consuming the high-dose diet died of 
pulmonary edema. It was concluded that 10 mg of FB1 per day into diet (500g), equivalent to 
ca. 0.7 mg/kg BW per day is safe for swine. A meta- analytical study of productive and 
nutritional interaction of mycotoxins in growing pigs demostrated that 87% of variance in 
weight gain was due to the feed intake (P˂0.01) and only 4% was due to the presence of 
mycotoxin in diets (P˂0.01) (Andretta et al., 2012). In the same meta-analysis, Andretta et al. 
(2012) concluded that fumonisins and zearalenone do not alter (P˃0.05) the pig feed intake. 
However, young animals are usually more sensitive to mycotoxins suggesting a less efficient 
elimination metabolism, which increase the resistance with maturity.   
Since liver and kidney are target organs for fumonisins, the fatty acid composition analysis 
of kidney and liver phospholipids and triglycerides was performed to test the effect of low 
dose of FB1 on piglets. Fatty acid composition was expressed as weight % of total FA methyl 
esters. Due to the lack of experiments in swine, the alterations in FAs profiles were compared 
only with studies on other species or doses.  
Kidney total phospholipids were analyzed. Alpha-linolenic acid (C18:3 n-3) provided a 
proportional decrease associated with mycotoxin treatment. In the study of Klaric et al. (2006) 
lipid peroxidation was tested on porcine kidney epithelial cells PK15. Cells were treated with 
0.05, 0.5 and 5 µg/ml of FB1 and the lipid peroxidation was calculated as a concentration of 
thiobarbituric acid-reacting substances (TBARS). The level of TBARS increased its 
concentration following a time-dependent rate demonstrating that porcine kidney cells are 
sensitive to fumonisin B1. Thus, lipid peroxidation could be the cause of the α-linolenic acid 
decrease. Moreover, we as well recorded the daily feed intake. Since alpha-linolenic acid is 
essential, its only source in the body lipids can be the diet. Thus, by unchanged dietary intake 
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its augmented damage may be the only reason of its decreased phospholipid level. From the 
saturated fatty acids, behenic acid (C22:0) and lignocerid acid (C24:0) showed similar 
alterations, namely lower proportions in the toxin treated animals. Thus, as a result of the 
latter two items, the total saturation decreased as well. Similar decrease of behenic acid was 
found in the study of Szabò et al. (2014) in rabbit tissues. The study analyzed the treatment 
of FB1 at 10 mg/kg of feed on red cell membrane fatty acid composition in weaned rabbits. 
The author suggested that this long chain fatty acid is an important component of 
sphingomyelins which is hydrolyzed by the enzyme sphingomyelinase to phosphorylcholine 
and ceramide. More recently in a study of Szabó et al. (2018), behenic acid depletion has been 
described again in the liver of FB1 treated rats. Ceramide is converted by the enzyme 
ceramidase into sphingosine, thus the inhibition of ceramide synthesis refers indirectly the 
decrease of the behenic acid (C22:0) proportion.   
As a single item form the indices comprising multiple toxin data the average chain length 
(ACL) was the only that provided increase in the toxin treated group. Most probably this is 
attributed to the fact that proportional changes happened mostly in case of fatty acids having 
C 20 chains (C20:4 n-6 and C20:3 n-6), strongly affecting the ACL value.  
The fatty acid composition of liver phospholipids was defined. However, FB1 was not a very 
potent modulator/disruptor of hepatic total phospholipid FA composition, neither inducing 
liver weight alteration. The dose applied (20 mg/kg feed) is a limit value for the pigs. Since 
this was not a very drastic treatment, gross pathological alterations were not expected. Indeed, 
the primary aim of the study was to attain FB1-associated effects on the intestinal microbiota. 
Thus, organ level alterations were monitored as a second goal. As a practical basis a 50 mg/kg 
rat study was used, in which only 5 days were enough to detect hepatic effects of FB1 (Szabó 
et al., 2016). However, piglets are generally more sensitive on FB1. Likewise in the kidney, 
alpha-linolenic acid (C18:3 n-3) proportion decreased as a result of lipid peroxidation 
(Gelderblom et al., 2001). Similarly, the long chain polyunsaturated n-3 FA, 
docosapentaenoic acid (C22:5 n-3) decreased significantly. In a recent study Szabó et al. 
(2016), docosapentaenoic acid proportion was decreased significantly in FB1 treated rabbits 
liver phospholipids. According to Abel et al. (2001), the proportional decrease of C20-C22 
FAs is a factor to control/improve antioxidant properties.  
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The proportional reduction of alpha-linolenic acid is probably due, like in the kidney, to the 
lipid peroxidation activity induced by the mycotoxin. Since alpha-linolenic acid is a precursor 
of decosapentaenoic acid, its reduction is associated with the absence of the precursor. 
Another change in the alteration of the lipid profile of phospholipids caused by FB1 is an 
increase in the proportion of arachidonic acid (C20:4 n-6). This result has no explanation 
since this alteration is confirmed only in in vitro studies in primary hepatocytes (Gelderblom 
et al., 2001). The increase of arachidonic acid could be caused by the disruption of 
prostaglandin biosynthesis by inhibiting the cyclooxygenase enzyme. It was shown, in vitro, 
that the mitoinhibitory effect of FB1 was contrasted by the addiction of prostaglandin E2. The 
total saturation level decreased. This is probably associated with the proportional increase of 
arachidonic acid and the proportional, but not significant, increase of the total mono-saturated 
fatty acids. Increase in mono unsaturated fatty acid was also observed in Szabó et al. (2016) 
and Gelderblom et al. (2002). In parallel, the total level of omega-3 fatty acids (FAs) 
decreased significantly. The increase of arachidonic acid proportion and the decrease of the 
n-3 FAs led to an increasing n-6 / n-3 FA ratio. 
The triglycerides were analysed as well in order to detect changings in FA composition. In 
the present study, kidney triglycerides did not response to the fumonisin B1 treatment. On the 
other hand, liver triglycerides denoted some proportional changes between the two groups. 
The proportion of stearic acid (C18:0) increased in the toxin treated group, as well as the 
proportion of arachidonic acid (C20:4 n-6), in the liver. The same proportional increase of 
arachidonic acid was observed in the analysis of liver phospholipids. Probably this acid being 
a precursor of the prostaglandin H2, which can be converted in prostaglandins, is involved in 
the contrasting of inflammatory processes caused by FB1. A slight decrease was found for 
lignoceric acid (C24:0). This result was obtained also in liver and kidney phospholipids. 
Unfortunately, we were not able to find any contradictive or supportive literature data for this 
finding. Most probably due to the alteration of arachidonic acid, the total omega-6 / omega-3 
fatty acids increased. However, the compositional changes of liver triglycerides are seldom 
reported and are generally a part of energy metabolism. Triglycerides stores have less other 
function than energy supply, and are thus mostly reflecting the needs of specific FAs at an 
extrahepatic site. Since we only registered minor changes, our triglycerides dataset may be 
handled as a secondary one. 
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5. Conclusion  
In this study the effect of a naturally contaminated diet with fumonisin B1 at 20 mg/kg of feed 
in a short period of 10 days in weaned piglets was assessed. The results showed a non-
response treatment on behaviour, productive parameters and organ weight values. Membrane 
fatty acid composition of liver and kidney was slightly responsive, suggesting ceramide 
synthesis disturbance. The most probable reason might be the low dose and short period of 
exposure to the toxin, even if swine are the most sensitive farm animal to this toxin. The slight 
changes of phospholipid fatty acid proportions observed in liver and kidneys, is maybe a 
consequence of the increased susceptibility to lipid peroxidation (Abel and Gelderblom 1998; 
WHO 2005). It would be interesting to analyse if the anti-oxidant defence system (non-
enzymatic, and even enzymatic) was activated even at a low contamination and in a short 
period. Results of the present study indicate that low, but realistic FB1 exposure for a limited 
time-frame has no drastic health or biochemical consequences, but is already detectable with 
sensitive techniques. However, production has not been compromised at the dose and 
exposure applied. 
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